scholarly journals S874 Comparative Efficacy of TNF Antagonists and Ustekinumab in Post-Operative Crohn’s Disease

2021 ◽  
Vol 116 (1) ◽  
pp. S409-S410
Author(s):  
Waseem Ahmed ◽  
Prerna Mahtani ◽  
Yushan Pan ◽  
Anjana Rajan ◽  
Daniel Lai ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Comparative Efficacy ◽  
Tnf Antagonists

Comparative Efficacy of Anti-TNF Therapies For The Prevention of Postoperative Recurrence of Crohn’s Disease

2019 ◽  
Vol 53 (6) ◽  
pp. 409-417 ◽  
Author(s):  
Ziad Bakouny ◽  
Fares Yared ◽  
Elie El Rassy ◽  
Rita Jabbour ◽  
Rachel Hallit ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Postoperative Recurrence ◽  
Comparative Efficacy

scholarly journals Azathioprine and Infliximab: Monotherapy or Combination Therapy in the Treatment of Crohn's Disease

2011 ◽  
Vol 4 ◽  
pp. CGast.S5256 ◽  
Author(s):  
Bryan L. Love ◽  
Lisa S. Smith ◽  
Steedman A. Sarbah ◽  
Fred C. Fowler
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Combination Therapy ◽  
Tumor Necrosis ◽  
Chronic Inflammatory Disease ◽  
First Line ◽  
Tnf Antagonists ◽  
Systemic Corticosteroids ◽  
Necrosis Factor

Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract often resulting in complications resulting in decreased quality of life. Several classes of medications are available to clinicians including mesalamine, budesonide, systemic corticosteroids, thiopurine derivatives, and monoclonal antibodies which target tumor necrosis factor (TNF). Guidelines generally recommend reserving TNF-antagonists for patients who have failed other first-line therapies; however, emerging data suggests there may be some benefit in combining TNF-antagonists, specifically infliximab, with azathioprine. The purpose of this review is to compare the benefits and risks of combination therapy, and identify patients who may benefit most from this approach.

scholarly journals Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists

2017 ◽  
Vol 6 (3) ◽  
pp. 439-445 ◽  
Author(s):  
Martine De Vos ◽  
Barbara Dhooghe ◽  
Severine Vermeire ◽  
Edouard Louis ◽  
Fazia Mana ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Clinical Response ◽  
Disease Activity Score ◽  
Real Life ◽  
Tnf Antagonists ◽  
Mayo Score ◽  
Medical Need ◽  
Remission Rates ◽  
Inflammatory Bowel

Background Vedolizumab is a recently available monoclonal antibody targeting α4β7 integrin for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD). Objective The objective of this article is to evaluate the efficacy of vedolizumab induction therapy in anti-TNF-refractory/intolerant UC and CD patients in real life. Methods A cohort of 149 moderately to severely active UC and CD patients who failed or showed intolerance to at least two TNF antagonists participated in a medical need program and received vedolizumab in 37 Belgian centers (April–September 2015). Rates of clinical response and remission were retrospectively evaluated at Week 10 for UC and Week 14 for CD using the physician’s global assessment (PGA), Mayo score and Harvey Bradshaw index (HBI) or Crohn's disease activity score (CDAI) scores. Results Eighty-four patients (29 UC, 55 CD) had sufficient data for analysis. For UC patients, clinical response was observed in 76% based on PGA and 59% based on the Mayo score. The corresponding percentages for CD patients were 80% for PGA and 65% for HBI/CDAI. Clinical remission rates were 10% and 40% for UC and CD, respectively. Steroid-free remission was observed in respectively 10% and 35%. Globally, corticosteroids were stopped in 14 out of 48 patients (29%). No new safety signals were reported. Conclusion Up to 70% TNF-refractory/intolerant UC and CD patients achieved a clinical response after 10 to 14 weeks of vedolizumab treatment in this real-life cohort.

Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists

2010 ◽  
Vol 77 (6) ◽  
pp. 625-626 ◽  
Author(s):  
Laure Brulhart ◽  
Michael J. Nissen ◽  
Paola Chevallier ◽  
Cem Gabay
Keyword(s):  
Crohn’S Disease ◽  
Ankylosing Spondylitis ◽  
Crohn's Disease ◽  
Tnf Antagonists
Sign in / Sign up

Export Citation Format

Share Document